Lobucavir is active not only against HIV, but also against the herpes simplex viruses HSV-1 and HSV-2, cytomegalovirus, and hepatitis B virus. [5] [6] [7] [8] [9] This wide scope has prompted us to look for similar or improved antiviral properties in analogues of lobucavir with a modified cyclobutane moiety. Although certain limited structure-activity relationships have been inferred for CANs, 10, 11) there are as yet no general rules of this kind.
Specifically, our aim has been to investigate the antiviral activity of a series of lobucavir analogues that i) lack the 2Ј-hydroxymethyl group of lobucavir, which makes them more like 3Ј-deoxynucleosides; ii) have a gem-dimethyl-substituted cyclobutane carbon that makes them more lipophilic and greatly restricts the conformational flexibility of the other substituents on the cyclobutane ring; and iii) have an extra methylene between the remaining hydroxymethyl group and the heterocyclic moiety, which further increases their lipophilicity but allows a certain degree of molecular flexibility. 12, 13) Among our first findings was that some of the simplest lobucavir analogues of this kind (compounds III) have no activity against the viruses inhibited by lobucavir, but do have marked activity against respiratory syncytial virus (IIIa and IIIb) or, to a lesser extent, against vaccinia virus (IIIc). 13) In addition, it has been reported that a 6Ј-C-methylneplanocin A (IVa) is more potent and/or selective than neplanocin A (IVb) against cytomegalovirus, vaccinia virus, parainfluenza virus, measles virus, respiratory syncytial virus, Junin virus, Tacaribe virus, vesicular stomatitis virus and reovirus. 14) This fact suggested to us to extend our research to compounds in which the cyclobutane ring bears a 1-hydroxyethyl group instead of the hydroxymethyl group of compounds III.
We have accordingly synthesized and assayed compounds of types V and VI, in the latter of which, additionally, lipophilicity and conformational flexibility have been further increased by inclusion of an extra methylene between the cyclobutane and heterocyclic moieties. The S-configuration for the 1-hydroxyethyl chain of V and VI was an unavoidable choice since the corresponding epimers were the only easily available ones via the reduction of the starting material, (Ϫ)-1R-cis-pinonic acid, with a variety of reagents.
Lobucavir analogues V or VI were synthesized by construction of an adenine or 8-azaadenine on the amino group of enantiomerically pure amino alcohols 1 or 2, 15) using the classical approach to carbocyclic analogues of nucleosides (Chart 1). 16, 17) Briefly, condensation of 1 or 2 with 5-amino-4,6-dichloropyrimidine afforded pyrimidinylamines 3 or 4, respectively, and cyclization of 3 or 4 with triethyl orthoformate gave the 6-chloropurines 5 or 6, which were converted to hypoxanthine analogues 7 or 8 by treatment with sodium hydroxide or to adenine analogues 9 or 10 by heating with concentrated aqueous ammonia. The 8-azaadenine derivatives were prepared by diazotizing 3 or 4 with sodium nitrite in hydrochloric acid and converting the resulting highly unstable 6-chloro-8-azapurines 11 or 12, without their prior isolation, into the 8-azahypoxanthine analogue 13 (by simply heating the crude reaction mixture) or the 8-azaadenine analogues 14 or 15 (by treatment with concentrated aqueous ammonia).
Using procedures described elsewhere, 18, 19) the antiviral activities of compounds 7-10 and 13-15 were evaluated in vitro against a variety of viruses. The viruses and host cells used were as follows: herpes simplex virus type 1 (strain KOS), herpes simplex virus type 2 (strain G), caccinia virus, vesicular stomatitis virus and thymidine kinase-deficient (TK All the new compounds were inactive in most of the tests performed, but some of them showed some activity in tests against vaccinia virus (VV) or respiratory syncytial virus (RSV). Table 1 shows the results obtained with the new compounds, together with those obtained with their analogues of type III and with two well-known standards. With regard to VV, the moderate activities of compounds 14 and 15 against this virus are similar to that of IIIc (like 14 and 15 a 6-amino-8-azapurine derivative), which shows that an extra methyl group on the carbon bearing the hydroxyl of these compounds does not greatly alter their anti-VV activity, which remains of a magnitude similar to that of ribavirin and well below that of brivudin. With regard to RSV, the marked activity of the 6-aminopurine IIIb (about 15-fold less than those of neplanocin A and 6Ј-C-methylneplanocin A, 14) but of the same magnitude as that of ribavirin and more than 130-fold more active than brivudin) is retained by the type V analogue 9 but not by the type VI analogue 10. Curiously, anti-RSV activity of the same magnitude as that of IIIb is displayed by the type VI hypoxanthine derivative 8, whereas the corresponding type V analogue 7 is inactive. Thus although the replacement of the hydroxymethyl of III by a 1-hydroxyethyl does not greatly alter the antiviral profile of these compounds, introduction of an extra methylene between the carbocycle and the heterocyclic system can have a marked effect one way or the other, probably because of the resulting increase in the flexibility of the molecule in this region.
The antitumoral activities of compounds 7-10 and 13-
Chart 1
15 were assayed against murine leukemia cells (L1210/0) and human T-lymphocytes (Molt4/C8 and CEM/0) using procedures described elsewhere. 19) Inhibitory concentrations 50 (IC 50 ), required to reduce cell growth by 50%, were Ͼ200 mg/ml for compounds with an oxygen at position 6 of the purine base (7, 13 and 8) and type V derivative 14. Highest cytostatic activities were measured for type VI derivatives 10 and 15, with IC 50 (Molt4/C8) of 101Ϯ62 and 110Ϯ6 mg/ml, respectively, and IC 50 (CEM/0) of 85Ϯ59 and 128Ϯ11 mg/ml, respectively.
Experimental
Melting points were determined on a Reichert Kofler thermopan and are uncorrected. Sodium D line polarimetry was carried out in a Perkin-Elmer 241 polarimeter. IR spectra of samples in KBr discs (solids) or as films between NaCl plates (oils) were recorded in a Perkin-Elmer FTIR 1640 spectrometer.
1 H-and 13 C-NMR spectra were recorded in a Bruker AMX-300 spectrometer at 300 and 75 MHz, respectively, with TMS as internal standard. Mass spectra were recorded on a Kratos MS-59 spectrometer. Silica gel (400 mesh) for flash chromatography (FC) was from Merck. Reagents and solvents were of commercial grade (Aldrich Chemical Co.).
(؉)-(1S,1R)-cis-1-[3-(5-Amino-6-chloropyrimidin-4-ylaminomethyl)-2,2-dimethylcyclobutyl]ethanol (3)
A solution of 1 (3.47 g, 22.10 mmol), 5-amino-4,6-dichloropyrimidine (4.30 g, 26.4 mmol) and triethylamine (14 ml) in dry 1-butanol (100 ml) was heated under reflux for 72 h. The reaction mixture was cooled and the solvent was removed in vacuo. Chromatography (3 : 2 CH 2 Cl 2 /EtOAc) gave 3 as a white solid (4.32 g, 69%). An analytical sample was obtained by recrystallization from cyclohexane/ EtOAc, mp 154-156°C. [ 
